|
SEC Working Group for the 2020 ESC Guidelines for the Management of Atrial Fibrillation; Expert Reviewers for the 2020 ESC Guidelines for the Management of Atrial Fibrillation; SEC Guidelines Committee; Working Group for the 2020 ESC guidelines for the management of atrial fibrillation; Expert reviewers for the 2020 ESC guidelines for the management of atrial fibrillation; SEC Guidelines Committee. Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2021 May;74(5):378-383. doi: 10.1016/j.rec.2020.11.023. Epub 2021 Mar 15. No abstract available. English, Spanish. PubMed PMID: 33736964.
AÑO: 2021
|
33736964
|
Ros-Lucas JA, Pascual-Figal DA, Noguera-Velasco JA, Hernandez-Vicente A, Cebreiros-Lopez I, Arnaldos-Carrillo M, Martinez-Ardil IM, Garcia-Vazquez E, Aparicio-Vicente M, Solana-Martinez E, Ruiz-Martinez SY, Fernandez-Mula L, Andujar-Espinosa R, Fernandez-Suarez B, Sanchez-Caro MD, Penalver-Mellado C, Ruiz-Lopez FJ. CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia. Sci Rep. 2022 Apr 25;12(1):6738. doi: 10.1038/s41598-022-10726-7. PubMed PMID: 35469047; PubMed Central PMCID: PMC9037059.
AÑO: 2022; IF: 4.6
|
|
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. PubMed PMID: 34861154.
AÑO: 2022; IF: 44.5
|
|
Palau P, Amiguet M, Dominguez E, Sastre C, Mollar A, Seller J, Garcia Pinilla JM, Larumbe A, Valle A, Gomez Doblas JJ, de la Espriella R, Minana G, Mezcua AR, Santas E, Bodi V, Sanchis J, Pascual-Figal D, Gorriz JL, Bayes-Genis A, Nunez J; DAPA-VO2 Investigators (see Appendix). Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2 ): a randomized clinical trial. Eur J Heart Fail. 2022 Oct;24(10):1816-1826. doi: 10.1002/ejhf.2560. Epub 2022 Jun 6. PubMed PMID: 35604416.
AÑO: 2022; IF: 18.2
|
|
SEC Working Group for the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice and SEC Guidelines Committee. Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed). 2022 May;75(5):364-369. doi: 10.1016/j.rec.2021.10.023. Epub 2022 Feb 11. No abstract available. English, Spanish. PubMed PMID: 35165071.
AÑO: 2022; IF: 5.9
|